6-Iodopravadoline (AM-630) is a cannabinoid receptor antagonist under development with the Univerisity of Wisconsin, USA, for potential use in the treatment of Anorexia nervosa. AM-630 is a selective CB2 receptor antagonist that binds to CB1 and CB2 receptors with Ki values of 5.2 μM and 31.2 nM, respectively. AM630 has been shown to display 165-fold selectivity over CB1 receptors and behave as a weak partial/inverse agonist at CB1 receptors. AM-630 acts as an inverse agonist on cloned human CB1 receptors. The efficacy of AM-630 in reducing the anxiety of the spontaneously anxious DBA/2 strain of mice strengthens the potential of the CB(2) receptor as a new target in the treatment of anxiety-related disorders.

SDB-006 is a cannabimimetic indole that binds the central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors with EC50 values of 19 and 134 nM, respectively. SDB-006 was discovered during research of the related compound JWH-018 adamantyl carboxamide, which has been sold illicitly in herbal blends.